During Q316 Transgene announced a collaboration agreement with Pfizer and Merck to develop TG4001 in combination with avelumab in a Phase I/II trial, the recruitment of the first patient in the multiple-dose cohort of Phase I/Ib of TG4001 in HBV patients and preclinical data from its vaccinia technology platform. The company plans to raise €48.1m (gross) through a rights issue that will fund operations to the end of 2018. Cash and equivalents at end Q316 amount to €25.4m. We value Transgene at €161.5m or €4.2/share.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs